Use filters to refine the search results.
Results 1-4 of 4
|20-May-2015||Final results of ProGem1, the first in-human phase I/II study of NUC-1031 in patients with solid malignancies||Blagden, SP; Rizzuto, I; Stavraka, C; O'Shea, D; Suppiah, P, et al|
|20-May-2015||A first in human Phase I/II study of NUC-1031 in patients with advanced gynecological cancers||Blagden, SP; Rizzuto, I; Stavraka, C; O'Shea, D; Suppiah, P, et al|
|1-Mar-2015||Risk of Ovarian Cancer Relapse Score A Prognostic Algorithm to Predict Relapse Following Treatment for Advanced Ovarian Cancer||Rizzuto, I; Stavraka, C; Chatterjee, J; Borley, J; Hopkins, TG, et al|
|2-Oct-2018||Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study||Blagden, SP; Rizzuto, I; Suppiah, P; O'Shea, D; Patel, M, et al|